The latest price target for Conmed (NYSE:CNMD) was reported by Needham on October 31, 2024. The analyst firm set a price target for $97.00 expecting CNMD to rise to within 12 months (a possible 41.34% upside). 16 analyst firms have reported ratings in the last year.

The latest analyst rating for Conmed (NYSE:CNMD) was provided by Needham, and Conmed reiterated their buy rating.

The last upgrade for Conmed Corp happened on March 27, 2023 when Keybanc raised their price target to $124. Keybanc previously had a sector weight for Conmed Corp.

There is no last downgrade for Conmed.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Conmed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Conmed was filed on October 31, 2024 so you should expect the next rating to be made available sometime around October 31, 2025.

While ratings are subjective and will change, the latest Conmed (CNMD) rating was a reiterated with a price target of $97.00 to $97.00. The current price Conmed (CNMD) is trading at is $68.63, which is out of the analyst’s predicted range.